Volume 2.33 | Sep 2

Mammary Cell News 2.33 September 2, 2010.
In this issue: Science News  |  Current Publications  |  Industry News  |  Policy News  |  Events Subscribe  |  Unsubscribe

TOP STORY

s-SHIP Promoter Expression Marks Activated Stem Cells in Developing Mouse Mammary Tissue  ShareThis
Researchers used the s-SHIP promoter to tag presumptive stem cells with GFP in the embryos of a transgenic mouse model. [Genes Dev]

Watch Procedure Now  
Learn to Enumerate Mammospheres and Tumorspheres
Cultured in MammoCult®
by STEMCELL Technologies
 
 
WATCH PROCEDURE NOW STEMCELL Technologies Inc
 



SCIENCE NEWS

Moderate Drinking May Boost Risk of Breast Cancer’s Return
Drinking even moderate amounts of alcohol may raise the risk for breast cancer recurrence in some women, new research indicates. [Press release from Bloomberg Businessweek discussing online prepublication in the Journal of Clinical Oncology]

Watch Procedure Now  
Use EpiCult-B® to Culture and Characterize
Human Mammary Epithelial Progenitors

by STEMCELL Technologies
 
 
CLICK HERE TO LEARN MORE STEMCELL Technologies Inc
 



CURRENT PUBLICATIONS (Ranked by Impact Factor of the Journal)

LABORATORY RESEARCH

Protease-Activated Receptors Mediate Cross-Talk Between Coagulation and Fibrinolysis
Researchers compared the protease-activated receptor-dependent expression of urokinase plasminogen activator and plasminogen activator inhibitor-1 in two murine mammary adencocarcinoma cell lines: metastatic 4T1 cells and non-metastatic 67NR cells. [Blood]

RNA Helicase A is a DNA-Binding Partner for EGFR-Mediated Transcriptional Activation in the Nucleus
Consistently, researchers observed a positive correlation of the nuclear expression of EGFR, RHA, and cyclin D1 in human breast cancer samples. [Proc Natl Acad Sci U S A]

Synergistic Chemosensitivity of Triple-Negative Breast Cancer Cell Lines to PARP Inhibition, Gemcitabine and Cisplatin
BRCA1 mutant cells exhibit sensitivity to gemcitabine, cisplatin and PARP inhibition, therefore, researchers hypothesized that triple negative cancer cells may also exhibit sensitivity to these drugs. [Cancer Res]

Secreted and Membrane-Bound Isoforms of Protease ADAM9 Have Opposing Effects on Breast Cancer Cell Migration
In this study, researchers show that ADAM9-S, a secreted variant, promotes breast cancer cell migration in a manner requiring its metalloprotease activity, whereas ADAM9-L, a transmembrane protein, suppresses cell migration independent of its metalloprotease activity. [Cancer Res]

Transforming Growth Factor-Beta-Induced Epithelial-Mesenchymal Transition Facilitates Epidermal Growth Factor-Dependent Breast Cancer Progression
Researchers show in this study that murine metastatic 4T1 breast cancer cells formed compact and dense spheroids when cultured under three-dimensional conditions, which was in sharp contrast to the branching phenotypes exhibited by their nonmetastatic counterparts. [Oncogene]

ITF2 is a Target of CXCR4 in MDA-MB-231 Breast Cancer Cells and is Associated with Reduced Survival in Estrogen Receptor-Negative Breast Cancer
Researchers propose that ITF2 is one of the CXCR4 targets, which is involved in CXCR4-dependent tumor growth and invasion of breast cancer cells. [Cancer Biol Ther]

CLINICAL RESEARCH

Alcohol Consumption and Breast Cancer Recurrence and Survival Among Women With Early-Stage Breast Cancer: The Life After Cancer Epidemiology Study
The purpose of this study was to examine the association of alcohol consumption after breast cancer diagnosis with recurrence and mortality among early-stage breast cancer survivors. [J Clin Oncol]

Molecular Anatomy of Breast Cancer Stroma and Its Prognostic Value in Estrogen Receptor-Positive and -Negative Cancers
The purpose of this study was to identify genes enriched in breast cancer stroma, assess the stromal gene expression differences between estrogen receptor (ER) -positive and -negative cancers, and separately determine their prognostic value in these two subtypes of breast cancers. [J Clin Oncol]



INDUSTRY NEWS

Eisai Announces Extension of FDA Review of Drug Application for Investigational Agent Eribulin Mesylate
Eisai Inc. announced that it has received notification from the U.S. Food and Drug Administration that the agency expects to complete priority review of the eribulin mesylate New Drug Application for locally advanced or metastatic breast cancer on or before December 30, 2010, which is a three month extension from the original Prescription Drug User Fee Act action date of September 30, 2010. [Eisai Inc. Press Release]

Ross Perot Commits $20 Million to UT MD Anderson Cancer Center
Dallas businessman and philanthropist H. Ross Perot has donated $20 million to The University of Texas MD Anderson Cancer Center for research to advance and design novel targeted therapies. [MD Anderson Cancer Center Press Release]



POLICY NEWS

Roche, Genentech Hit with Refuse-to-File Letter
The FDA has handed Roche and Genentech a refuse-to-file letter for the developers’ BLA for trastuzumab-DM1. [Food and Drug Administration, United States]

NIH Director Collins Says Cell Ruling Won’t Halt Most Ongoing Grants
National Institutes of Health (NIH) Director Francis Collins said that the court injunction blocking federally funded research on human embryonic stem cells will not affect grant payments that have already gone out the door this year. [National Institutes of Health, United States]

NIH Director’s Response to Stem Cell Injunction [National Institutes of Health, United States]

Office of the Director, National Institutes of Health; Notice of Meeting (FR Doc. 2010-20861) [National Institutes of Health, United States]

Center for Scientific Review; Notice of Closed Meetings (FR Doc. 2010-21357) [National Institutes of Health, United States]

National Cancer Institute; Notice of Closed Meeting (FR Doc. 2010-21282) [National Institutes of Health, United States]

National Human Genome Research Institute; Notice of Closed Meeting (FR Doc. 2010-21317) [National Institutes of Health, United States]

National Human Genome Research Institute; Notice of Meetings (FR Doc. 2010-20858) [National Institutes of Health, United States]



EVENTS (Listed by Date)

Stem Cells USA & Regenerative Medicine Congress 2010
September 13-15, 2010
Philadelphia, United States

15th Congress of the European Society of Surgical Oncology (ESSO)
September 15-17, 2010
Bordeaux, France

Cellular Therapy of Cancer Symposium – ATTACK Project Meeting
September 24-27, 2010
Montpellier, France

International Society for Cellular Therapy 2nd Annual Symposium on Stem Cell Translation: Best Practices & Regulatory Considerations
September 27-28, 2010
San Francisco, United States

Expert Perspectives: Integrating New Data into Best Practices for Breast Cancer
October 1, 2010
National Harbor, United States

2010 Breast Cancer Symposium
October 1-3, 2010
Washington, DC, United States

2nd International Inflammatory Breast Cancer Conference
October 6-7, 2010
Marseille, France

35th European Society for Medical Oncology (ESMO) Congress
October 8-12, 2010
Milan, Italy

New York Stem Cell Foundation Fifth Annual Translational Stem Cell Research Meeting
October 12-13, 2010
New York, United States

International Symposium on Breast Cancer Prevention: Nutrition, Communications, Public Policy
October 18-19, 2010
West Lafayette, United States

16th World Congress of the International Society of Senology
October 20-22, 2010
Valencia, Spain

The 2010 American Institute for Cancer Research (AICR) Annual Research Conference on Food, Nutrition, Physical Activity & Cancer
October 21-22, 2010
Washington, DC, United States

MENA Oncology Conference
October 22-23, 2010
Cairo, Egypt

UAE Cancer Congress 2010
October 28-30, 2010
Dubai, United Arab Emirates

6th National Cancer Research Institute (NCRI) Conference
November 7-10, 2010
Liverpool, United Kingdom

22nd EORTC-NCI-AACR Symposium on “Molecular Targets and Cancer Therapeutics”
November 16-19, 2010
Berlin, Germany

33rd Annual San Antonio Breast Cancer Symposium
December 8-12, 2010
San Antonio, United States

Visit our events page to stay up to date with the latest events in the cell, gene and immunotherapy community.


JOB OPPORTUNITIES

Cell Therapy Technologist (Opexa Therapeutics)

Recruit Top Talent
Reach more than 11,000 potential candidates by posting your organization’s career opportunities with Cell Therapy News.
Visit here to post your career opportunities.


Have we missed an important article or publication in Mammary Cell News? Click here to submit!


Learn more about Mammary Cell News: Archives  |  Events  |  Subscribe  |  Contact Us